News

American Association of Individual Investors3d
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 13.59%
Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 13.59%, which has investors questioning if this is right time ...
MedPage Today3h
Wristband Nerve Stimulator Improves Essential Tremor Outcomes
At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses
Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...
KLP Kapitalforvaltning AS Buys New Stake in Gibraltar Industries, Inc. (NASDAQ:ROCK)
KLP Kapitalforvaltning AS purchased a new stake in Gibraltar Industries, Inc. (NASDAQ:ROCK – Free Report) during the fourth ...
LPL Financial LLC Acquires 16,608 Shares of Invesco BulletShares 2025 Municipal Bond ETF (NASDAQ:BSMP)
LPL Financial LLC lifted its holdings in shares of Invesco BulletShares 2025 Municipal Bond ETF (NASDAQ:BSMP – Free Report) ...
pharmaphorum3d
After ph2 win, Cerevance preps pivotal trials of novel Parkinson's drug
Inhibikase Therapeutics is meanwhile running early-stage trials of a c-Abl inhibitor and Denali Therapeutics/Biogen are working on an LRRK2 inhibitor in Parkinson's, both hoping to show that the ...